Effect of Probiotic Administration Immediately and 1 Month after Colonoscopy in Diarrhea-predominant Irritable Bowel Syndrome Patients

Mahsa Khodadoostan, Ahmad Shavakhi, Zahra Sherafat, Alireza Shavakhi, Mahsa Khodadoostan, Ahmad Shavakhi, Zahra Sherafat, Alireza Shavakhi

Abstract

Background: Irritable bowel syndrome (IBS) is one of the most common disorders among young adults. Various studies have demonstrated that the use of probiotics can reduce the overall symptom of IBS, and thus, our aim was to evaluate the efficacy of probiotic products in the reduction of IBS syndrome after colonoscopy.

Materials and methods: Our patients were divided among three groups, including immediate probiotic users, start use of probiotics 1 month after colonoscopy, and placebo group. All the patients were interviewed for having common IBS symptoms (stool consistency and frequency, gas, abdominal pain, and flatulence) at baseline, 3rd month of follow-up, and 6th month of follow-up.

Results: The mean reduction in abdominal pain was 3.05 ± 1.21, 3.86 ± 0.94, and 3.82 ± 0.63 in the control group, immediate probiotic users, and 1 month after colonoscopy, respectively (P < 0.001). The symptoms of the disease, such as stool consistency, the frequency of defecation, and flatulence (except gas) in the first quarter, in the two treatment groups were significantly improved more than in the control group (P < 0.05). In contrast, the frequency of defecation was not significantly different in the treatment group receiving the probiotics month after colonoscopy compared to the placebo users (P > 0.05).

Conclusion: According to our results, the use of probiotics had the beneficial effect on IBS symptoms. Furthermore, it can be said that reductions in symptoms and pain in the two treatment groups were not significantly different, but after 6 months of treatment, the effect of probiotics in patients who immediately use it after colonoscopy was more visible and more stable.

Keywords: Clinical trial; irritable bowel syndrome; probiotics; symptoms of disease.

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
The linear graph based on the average of abdominal pain of all three groups. P1: The significance level of the comparison placebo with probiotics immediately. P2: The significance level of the comparison placebo with probiotics 1 month later. P3: The significance level of the comparison probiotics immediately with probiotics 1 month later. P4: The significance level of the comparison follow-up treatment in each group
Figure 2
Figure 2
The linear graph based on the average of flatulence of all three groups. P1: The significance level of the comparison placebo with probiotics immediately. P2: The significance level of the comparison placebo with probiotics 1 month later. P3: The significance level of the comparison probiotics immediately with probiotics 1 month later. P4: The significance level of the comparison follow-up treatment in each group

References

    1. Mugie SM, Benninga MA, Di Lorenzo C. Epidemiology of constipation in children and adults: A systematic review. Best Pract Res Clin Gastroenterol. 2011;25:3–18.
    1. Maxion-Bergemann S, Thielecke F, Abel F, Bergemann R. Costs of irritable bowel syndrome in the UK and US. Pharmacoeconomics. 2006;24:21–37.
    1. Mönnikes H. Quality of life in patients with irritable bowel syndrome. J Clin Gastroenterol. 2011;45:S98–101.
    1. Mullin GE, Shepherd SJ, Chander Roland B, Ireton-Jones C, Matarese LE. Irritable bowel syndrome: Contemporary nutrition management strategies. JPEN J Parenter Enteral Nutr. 2014;38:781–99.
    1. Drossman DA, Chang L, Bellamy N, Gallo-Torres HE, Lembo A, Mearin F, et al. Severity in irritable bowel syndrome: A Rome foundation working team report. Am J Gastroenterol. 2011;106:1749–59.
    1. Hasler WL. Traditional thoughts on the pathophysiology of irritable bowel syndrome. Gastroenterol Clin North Am. 2011;40:21–43.
    1. Camilleri M, Katzka DA. Irritable bowel syndrome: Methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2012;302:G1075–84.
    1. Eswaran S, Tack J, Chey WD. Food: The forgotten factor in the irritable bowel syndrome. Gastroenterol Clin North Am. 2011;40:141–62.
    1. Rosania R, Giorgio F, Principi M, Amoruso A, Monno R, Di Leo A, et al. Effect of probiotic or prebiotic supplementation on antibiotic therapy in the small intestinal bacterial overgrowth: A comparative evaluation. Curr Clin Pharmacol. 2013;8:169–72.
    1. NIH HMP Working Group, Peterson J, Garges S, Giovanni M, McInnes P, Wang L, et al. The NIH human microbiome project. Genome Res. 2009;19:2317–23.
    1. Collins SM. A role for the gut microbiota in IBS. Nat Rev Gastroenterol Hepatol. 2014;11:497–505.
    1. Hong SN, Rhee PL. Unraveling the ties between irritable bowel syndrome and intestinal microbiota. World J Gastroenterol. 2014;20:2470–81.
    1. Whelan K, Quigley EM. Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease. Curr Opin Gastroenterol. 2013;29:184–9.
    1. Whelan K. Probiotics and prebiotics in the management of irritable bowel syndrome: A review of recent clinical trials and systematic reviews. Curr Opin Clin Nutr Metab Care. 2011;14:581–7.
    1. Dalrymple J, Bullock I. Diagnosis and management of irritable bowel syndrome in adults in primary care: Summary of NICE guidance. BMJ. 2008;336:556–8.
    1. Church J. Complications of colonoscopy. Gastroenterol Clin North Am. 2013;42:639–57.
    1. Didari T, Solki S, Mozaffari S, Nikfar S, Abdollahi M. A systematic review of the safety of probiotics. Expert Opin Drug Saf. 2014;13:227–39.
    1. Drago L, Toscano M, De Grandi R, Casini V, Pace F. Persisting changes of intestinal microbiota after bowel lavage and colonoscopy. Eur J Gastroenterol Hepatol. 2016;28:532–7.
    1. Dapoigny M, Piche T, Ducrotte P, Lunaud B, Cardot JM, Bernalier-Donadille A, et al. Efficacy and safety profile of LCR35 complete freeze-dried culture in irritable bowel syndrome: A randomized, double-blind study. World J Gastroenterol. 2012;18:2067–75.
    1. Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O'Mahony L, et al. Efficacy of an encapsulated probiotic bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101:1581–90.
    1. Guyonnet D, Chassany O, Ducrotte P, Picard C, Mouret M, Mercier CH, et al. Effect of a fermented milk containing bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: A multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther. 2007;26:475–86.
    1. Lasser RB, Bond JH, Levitt MD. The role of intestinal gas in functional abdominal pain. N Engl J Med. 1975;293:524–6.
    1. O’Sullivan MA, O’Morain CA. Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Dig Liver Dis. 2000;32:294–301.
    1. Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, Dubuquoy L, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med. 2007;13:35–7.
    1. Kajander K, Myllyluoma E, Rajilić-Stojanović M, Kyrönpalo S, Rasmussen M, Järvenpää S, et al. Clinical trial: Multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther. 2008;27:48–57.
    1. Elsenbruch S. Abdominal pain in irritable bowel syndrome: A review of putative psychological, neural and neuro-immune mechanisms. Brain Behav Immun. 2011;25:386–94.
    1. Cui S, Hu Y. Multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Int J Clin Exp Med. 2012;5:238–44.
    1. Simrén M, Ohman L, Olsson J, Svensson U, Ohlson K, Posserud I, et al. Clinical trial: The effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome – A randomized, double-blind, controlled study. Aliment Pharmacol Ther. 2010;31:218–27.
    1. Didari T, Mozaffari S, Nikfar S, Abdollahi M. Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. World J Gastroenterol. 2015;21:3072–84.
    1. Azpiroz F, Bouin M, Camilleri M, Mayer EA, Poitras P, Serra J, et al. Mechanisms of hypersensitivity in IBS and functional disorders. Neurogastroenterol Motil. 2007;19:62–88.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅